InterMune Soars on IPF Study That May Support Approval
This article is for subscribers only.
InterMune Inc. rose the most ever after its drug pirfenidone for a fatal lung disease met goals of a study expected to support U.S. approval.
InterMune more than doubled to $37.80 at the close in New York for the shares’ biggest single-day increase since the company had its initial public offering in March 2000. The stock has more than quadrupled in the last year.